Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Intercept Pharmaceuticals, Inc.    ICPT

INTERCEPT PHARMACEUTICALS, INC.

(ICPT)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/30/2020 12/01/2020 12/02/2020 12/03/2020 12/04/2020 Date
35.51(c) 35.69(c) 36.61(c) 35.2(c) 35.4(c) Last
977 049 587 748 546 093 453 841 751 848 Volume
-4.72% +0.51% +2.58% -3.85% +0.57% Change
More quotes
Financials (USD)
Sales 2020 314 M - -
Net income 2020 -266 M - -
Net Debt 2020 - - -
P/E ratio 2020 -4,33x
Yield 2020 -
Sales 2021 361 M - -
Net income 2021 -232 M - -
Net cash position 2021 186  - -
P/E ratio 2021 -5,49x
Yield 2021 -
Capitalization 1 168 M 1 168 M -
Capi. / Sales 2020 3,72x
EV / Sales 2021 2,72x
Nbr of Employees 583
Free-Float 84,3%
More Financials
Company
Intercept Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company's product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions. The Company's product candidate, obeticholic acid (OCA), is a bile acid analog,... 
More about the company
Notations Surperformance© of Intercept Pharmaceuticals, Inc.
Trading Rating : Investor Rating :
More Ratings
All news about INTERCEPT PHARMACEUTICALS, INC.
12/03INTERCEPT PHARMACEUTICALS : Notice of Lead Plaintiff Deadline for Shareholders i..
BU
12/03SHAREHOLDER ALERT : Pomerantz Law Firm Reminds Shareholders with Losses on their..
PR
11/25INTERCEPT PHARMACEUTICALS : To present at the piper sandler 32nd annual virtual ..
AQ
11/24INTERCEPT PHARMACEUTICALS : ROSEN, A LEADING LAW FIRM, Reminds Intercept Pharmac..
PR
11/24INTERCEPT PHARMACEUTICALS : to Present at the Piper Sandler 32nd Annual Virtual ..
AQ
11/24Intercept to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conf..
GL
11/20INTERCEPT PHARMACEUTICALS : ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Reminds..
BU
11/20GLANCY PRONGAY & MURRAY LLP : Reminds Investors of Looming Deadline in the Class..
PR
11/18INTERCEPT PHARMACEUTICALS : The Law Offices of Frank R. Cruz Announces the Filin..
PR
11/17INTERCEPT PHARMACEUTICALS, INC. : Change in Directors or Principal Officers (for..
AQ
11/17ICPT SHAREHOLDER ALERT : Bronstein, Gewirtz & Grossman, LLC Reminds Intercept Ph..
BU
11/16INTERCEPT PHARMACEUTICALS : New Data from the Interim Analysis of REGENERATE Sho..
AQ
11/16New Data from the Interim Analysis of REGENERATE Show OCA Improved Noninvasiv..
GL
11/14INTERCEPT PHARMACEUTICALS : ROSEN, RESPECTED INVESTOR COUNSEL, Announces Filing ..
PR
11/13DEADLINE REMINDER : Law Offices of Howard G. Smith Reminds Investors of Looming ..
BU
More news
News in other languages on INTERCEPT PHARMACEUTICALS, INC.
06/29WALL STREET STOCK EXCHANGE : Les valeurs à suivre à Wall Street
05/12Genfit s'effondre en Bourse après l'échec d'Elafibranor, son produit phare
02/20Molecular Partners prévoit un triple remplacement au sein de son conseil
2019EN DIRECT DES MARCHES : Renault, Air France, Seb, Tarkett, Genfit, Tesla, For..
2019STOCK MARKET PARIS : En pause en attendant la Fed
More news
Chart INTERCEPT PHARMACEUTICALS, INC.
Duration : Period :
Intercept Pharmaceuticals, Inc. Technical Analysis Chart | ICPT | US45845P1084 | MarketScreener
Technical analysis trends INTERCEPT PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 56,39 $
Last Close Price 35,40 $
Spread / Highest target 228%
Spread / Average Target 59,3%
Spread / Lowest Target -6,78%
EPS Revisions
Managers
NameTitle
Mark E. Pruzanski President, Chief Executive Officer & Director
Paolo Fundarò Chairman
Jerome B. Durso Chief Operating Officer
Sandipkumar S. Kapadia Chief Financial Officer & Treasurer
Christian Weyer Executive Vice President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
INTERCEPT PHARMACEUTICALS, INC.-71.43%1 168
GILEAD SCIENCES, INC.-5.26%77 167
VERTEX PHARMACEUTICALS4.28%59 372
REGENERON PHARMACEUTICALS31.15%51 975
WUXI APPTEC CO., LTD.68.65%41 218
BIONTECH SE254.19%28 894